This is the top biotech stock pick from B Riley Securities

B. Riley reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics after the company began enrolling patients in the 4SIGHT Phase 3 diabetic macular edema trial and reported encouraging two-year 4D-150 data. At the Phase 3 dose, 4D-150 delivered a 10.8-letter vision gain with 5.2 supplemental injections on average after loading doses, with no intraocular inflammation or ocular serious adverse events among 22 patients. The broker estimates risk-adjusted peak global sales of $1.44 billion for 4D-150 and projects 8-12 procedures over five years, versus roughly 34 for aflibercept.

Analysis

FDMT's investability now hinges less on modeled procedure reduction than on whether durable expression translates into a commercially usable safety/retreatment profile across a far larger population. A 22-patient durability dataset cannot yet underwrite the broker's risk-adjusted revenue case: gene-therapy ocular programs can show delayed inflammation, variable transduction, and irreversible-treatment concerns that only emerge with broader exposure. The three registrational studies create a meaningful readout sequence, but also concentrate clinical, manufacturing, and financing risk in a pre-commercial small-cap.

The competitive issue is segmentation, not simply injection frequency. Roche's Vabysmo and Regeneron's Eylea HD retain physician familiarity, flexible rescue dosing, and established reimbursement; FDMT must demonstrate that fewer visits outweigh reluctance to use a non-redosable therapy in eyes with heterogeneous anti-VEGF needs. KOD's data underscore that a meaningful subset of patients requires more frequent treatment, which could become the key adoption constraint for a fixed-expression product. If FDMT validates a low-rescue-injection rate, it could pressure anti-VEGF procedure volumes and favor retina practices able to absorb a one-time, potentially high-ticket intervention—but payers may demand step therapy and multi-year outcomes before broad uptake.

Near term, the analyst reiteration is unlikely to re-rate FDMT sustainably absent enrollment execution, cash-runway clarity, or incremental durability data. Over 6-18 months, the equity is a binary clinical optionality vehicle: a clean Phase 3 profile could support substantial upside versus a $37 target framework, while inflammation, rescue-treatment needs, or weak durability would impair both probability of approval and peak-sales assumptions simultaneously. The contrarian view is that the market may correctly discount the theoretical visit-burden advantage until reimbursement economics and late safety are visible; fewer injections do not automatically translate to payer savings if upfront pricing is gene-therapy-like.

Key Decisions for Investors

• Maintain FDMT as a small, event-driven long only; do not chase on the rating reiteration. Add only after confirmation of enrollment pace and updated cash runway, with sizing consistent with a Phase 3 binary outcome and a 12-24 month horizon.
• Use KOD as the cleaner relative watch: long FDMT/short KOD is appropriate only if FDMT reports durable efficacy with low rescue injections and no inflammation in a materially expanded cohort. Until then, KOD has lower platform-validation risk and the pair lacks a confirmed catalyst edge.
• Set a diligence trigger on FDMT quarterly filings: reassess immediately if projected cash runway falls short of the next material Phase 3 data event or if equity issuance materially expands share count; financing dilution can overwhelm clinical-progress upside in the next 3-9 months.
• Falsify the FDMT long thesis if expanded safety data show intraocular inflammation or ocular serious adverse events, or if supplemental injection rates converge toward Vabysmo/Eylea HD treatment intensity. Either result would undermine the differentiation required to support premium adoption and the modeled peak-sales case.
• Avoid treating APP and SMCI as read-throughs; their presence in the supplied ticker set is not economically connected to retinal gene therapy and creates no actionable cross-asset implication.